Allogeneic CD33-redirected CAR-T cells(Center for International Blood and Marrow Transplant Research)(Allogeneic CD33-redirected CAR-T cells(Center for International Blood and Marrow Transplant Research))

概要

基本信息

药物类型

间充质干细胞疗法

别名-

靶点

CD33

作用方式

调节剂

作用机制

CD33调节剂(髓系细胞表面抗原CD33调节剂)

治疗领域-

在研适应症-

非在研适应症-

原研机构

Center for International Blood & Marrow Transplant Research

在研机构

Center for International Blood & Marrow Transplant Research

非在研机构-

权益机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Allogeneic CD33-redirected CAR-T cells(Center for International Blood and Marrow Transplant Research) 相关的临床试验

NCT03971799

/ Recruiting临床1/2期IIT

Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia

This phase 1/2 trial aims to determine the safety and feasibility of antiCD33 chimeric antigen receptor (CAR) expressing T cells (CD33CART) in children and adolescents/young adults (AYAs) with relapsed/refractory acute myeloid leukemia (AML). The trial will be done in two phases: Phase 1 will determine the maximum tolerated dose of CD33CART cells using a 3+3 trial design, with dose-escalation for autologous products separated from dose-escalation for an allogeneic arm. Phase 2 is an expansion phase designed to evaluate the rate of response to CD33CART.

开始日期2020-01-08

申办/合作机构

Center for International Blood & Marrow Transplant Research

[+2]

100 项与 Allogeneic CD33-redirected CAR-T cells(Center for International Blood and Marrow Transplant Research) 相关的临床结果

登录后查看更多信息

100 项与 Allogeneic CD33-redirected CAR-T cells(Center for International Blood and Marrow Transplant Research) 相关的转化医学

登录后查看更多信息

100 项与 Allogeneic CD33-redirected CAR-T cells(Center for International Blood and Marrow Transplant Research) 相关的专利（医药）

登录后查看更多信息

100 项与 Allogeneic CD33-redirected CAR-T cells(Center for International Blood and Marrow Transplant Research) 相关的药物交易

登录后查看更多信息